Postmenopausal Vaginal Atrophy Market 2022
- 10 years ago
Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-postmenopausal-vaginal-atrophy-global-drug-forecast-and-market-analysis-to-2022-market-report.html .
Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade, it is expected to undergo a considerable change between 2012 and 2022. This market has historically had a large untreated population due to: low diagnosis rates, safety issues with the existing therapies, and poor patient compliance. Since the mainstay estrogen-based therapies are associated with causing elevated risk for breast cancer, endometrial cancer, and stroke, many women go untreated. However, the launches of three novel drugs with improved safety profiles Osphena (ospemifene), Vaginorm (prasterone), and BZA/CE (bazedoxifene + conjugated estrogens) have the potential to tap into the large pool of untreated patients. These non-estrogenic therapies will also shift the PVA treatment paradigm away from systemic estrogen therapies (ETs), such as pills, patches, and gels. Furthermore, awareness campaigns surrounding product launches will likely boost treatment-seeking behavior for the PVA market as a whole. Ultimately these dynamics will be reflected in the moderate growth of the overall PVA market during the forecast period, which will increase from $1.10b in 2012 to $2.1b in 2022 at a Compound Annual Growth Rate (CAGR) of 5.9%.
Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade, it is expected to undergo a considerable change between 2012 and 2022. This market has historically had a large untreated population due to: low diagnosis rates, safety issues with the existing therapies, and poor patient compliance. Since the mainstay estrogen-based therapies are associated with causing elevated risk for breast cancer, endometrial cancer, and stroke, many women go untreated. However, the launches of three novel drugs with improved safety profiles Osphena (ospemifene), Vaginorm (prasterone), and BZA/CE (bazedoxifene + conjugated estrogens) have the potential to tap into the large pool of untreated patients. These non-estrogenic therapies will also shift the PVA treatment paradigm away from systemic estrogen therapies (ETs), such as pills, patches, and gels. Furthermore, awareness campaigns surrounding product launches will likely boost treatment-seeking behavior for the PVA market as a whole. Ultimately these dynamics will be reflected in the moderate growth of the overall PVA market during the forecast period, which will increase from $1.10b in 2012 to $2.1b in 2022 at a Compound Annual Growth Rate (CAGR) of 5.9%.